Verona Pharma plc financial data

Symbol
VRNA on Nasdaq
Industry
Pharmaceutical Preparations
Location
3 More London Riverside, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 10, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.59K % +219%
Debt-to-equity 18.2 % -0.93%
Return On Equity -25.1 % +11.4%
Return On Assets -21.2 % +11.3%
Operating Margin -16.5K % -8924%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 649M shares +2.65%
Common Stock, Shares, Outstanding 647M shares +2.43%
Entity Public Float 1.5B USD +607%
Common Stock, Value, Issued 42.8M USD +2.44%
Weighted Average Number of Shares Outstanding, Basic 646M shares +3.9%
Weighted Average Number of Shares Outstanding, Diluted 646M shares +3.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD -100%
Cost of Revenue 0 USD -100%
Research and Development Expense 17.2M USD -65.1%
General and Administrative Expense 61.2M USD +113%
Operating Income (Loss) -72.6M USD +0.43%
Nonoperating Income (Expense) 10.2M USD -19.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -62.4M USD -3.49%
Income Tax Expense (Benefit) 1.06M USD +207%
Net Income (Loss) Attributable to Parent -63.4M USD -4.64%
Earnings Per Share, Basic -0.1 USD/shares +9.09%
Earnings Per Share, Diluted -0.1 USD/shares +9.09%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 255M USD -12.5%
Other Assets, Current 1.88M USD -9.55%
Assets, Current 272M USD -11.4%
Property, Plant and Equipment, Net 22K USD +83.3%
Operating Lease, Right-of-Use Asset 2.51M USD +259%
Goodwill 545K USD 0%
Assets 290M USD -10.3%
Accounts Payable, Current 4.65M USD -35.7%
Employee-related Liabilities, Current 2.69M USD +235%
Accrued Liabilities, Current 8.27M USD -53.3%
Liabilities, Current 14.8M USD -44.3%
Operating Lease, Liability, Noncurrent 1.6M USD +2368%
Liabilities 64.9M USD +39.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -4.6M USD 0%
Retained Earnings (Accumulated Deficit) -414M USD -18.4%
Stockholders' Equity Attributable to Parent 225M USD -18.7%
Liabilities and Equity 290M USD -10.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -13.6M USD -135%
Net Cash Provided by (Used in) Financing Activities -3.12M USD -105%
Net Cash Provided by (Used in) Investing Activities -16K USD
Common Stock, Shares, Issued 668M shares +2.46%
Common Stock, Par or Stated Value Per Share 0.05 GBP/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -16.9M USD -127%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 255M USD -12.5%
Interest Paid, Excluding Capitalized Interest, Operating Activities 933K USD +282%
Deferred Tax Assets, Valuation Allowance 55.5M USD +14.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.24 pure +21.1%
Deferred Tax Assets, Gross 109M USD +31.7%
Operating Lease, Liability 2.96M USD +236%
Payments to Acquire Property, Plant, and Equipment 16K USD
Lessee, Operating Lease, Liability, to be Paid 3.59M USD +296%
Operating Lease, Liability, Current 1.12M USD +72%
Lessee, Operating Lease, Liability, to be Paid, Year Two 842K USD +292%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.18M USD +74.1%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 634K USD +2248%
Lessee, Operating Lease, Liability, to be Paid, Year Three 788K USD +4535%
Deferred Tax Assets, Operating Loss Carryforwards 54M USD +38.9%
Current Income Tax Expense (Benefit) 474K USD +87.4%
Lessee, Operating Lease, Liability, to be Paid, Year Four 784K USD
Additional Paid in Capital 602M USD +1.96%
Depreciation, Depletion and Amortization 263K USD +67.5%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 19M USD +29.4%
Interest Expense 3.35M USD +359%